ReviewAlimentary pharmacology & therapeutics2010
Review article: new receptor targets for medical therapy in irritable bowel syndrome.
Review in Alimentary pharmacology & therapeutics, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 55 citations in OpenAlex.
- Pilot trial: pregabalin on colonic sensorimotor functions in irritable bowel syndrome.Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver · 2014Trial
- Effect of the α2δ ligand, pregabalin, on colonic sensory and motor functions in healthy adults.American journal of physiology. Gastrointestinal and liver physiology · 2011Trial
- Investigating the causal roles of cholesterol and triglyceride subfractions across lipoproteins in irritable bowel syndrome: a Mendelian randomization study.Metabolism open · 2026Article
- The gastrointestinal endothelin system: receptors, cellular actions, and involvement in gastrointestinal disorders.Przeglad gastroenterologiczny · 2025Review
- Managing gastrointestinal manifestations in systemic sclerosis, a mechanistic approach.Expert review of clinical immunology · 2024Review
- A Mendelian randomization study on the effects of plasma lipids on irritable bowel syndrome and functional dyspepsia.Scientific reports · 2024Article
- Gut-brain Axis and migraine headache: a comprehensive review.The journal of headache and pain · 2020Review
- Medical Therapies in the Pipeline for Irritable Bowel Syndrome.Gastroenterology & hepatology · 2017Article
- Interplay between mast cells, enterochromaffin cells, and sensory signaling in the aging human bowel.Neurogastroenterology and motility · 2016Article
- Chemotherapy-Induced Constipation and Diarrhea: Pathophysiology, Current and Emerging Treatments.Frontiers in pharmacology · 2016Review
- Comparison of Electroacupuncture and Moxibustion for Relieving Visceral Hypersensitivity in Rats with Constipation-Predominant Irritable Bowel Syndrome.Evidence-based complementary and alternative medicine : eCAM · 2016Article
- Herbal prescription Chang'an II repairs intestinal mucosal barrier in rats with post-inflammation irritable bowel syndrome.Acta pharmacologica Sinica · 2015Article
- Optimal management of constipation associated with irritable bowel syndrome.Therapeutics and clinical risk management · 2015Review
- Impact of psychological stress on irritable bowel syndrome.World journal of gastroenterology · 2014Review
- ZD 7288, an HCN channel blocker, attenuates chronic visceral pain in irritable bowel syndrome-like rats.World journal of gastroenterology · 2014Article
- Release characteristics of quetiapine fumarate extended release tablets under biorelevant stress test conditions.AAPS PharmSciTech · 2014Article
- The gut as a sensory organ.Nature reviews. Gastroenterology & hepatology · 2013Article
- Linaclotide.Hospital pharmacy · 2013Article
- New treatments for IBS.Nature reviews. Gastroenterology & hepatology · 2013Review
- Drug development for the irritable bowel syndrome: current challenges and future perspectives.Frontiers in pharmacology · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
backgroundDespite setbacks to the approval of new medications for the treatment of irritable bowel syndrome, interim guidelines on endpoints for irritable bowel syndrome (IBS) trials have enhanced interest as new targets for medical therapy are proposed based on novel mechanisms or chemical entities.
aimsTo review the approved lubiprostone, two targets that are not meeting expectations (tachykinins and corticotrophin-releasing hormone), the efficacy and safety of new 5-HT(4) agonists, intestinal secretagogues (chloride channel activators, and guanylate cyclase-C agonists), bile acid modulation, anti-inflammatory agents and visceral analgesics.
methodsReview of selected articles based on PubMed search and clinically relevant information on mechanism of action, safety, pharmacodynamics and efficacy.
resultsThe spectrum of peripheral targets of medical therapy addresses chiefly the bowel dysfunction of IBS and these effects are associated with pain relief. The pivotal mechanisms responsible for the abdominal pain or visceral sensation in IBS are unknown. The new 5-HT(4) agonists are more specific than older agents and show cardiovascular safety to date. Secretory agents have high specificity, low bioavailability and high efficacy. The potential risks of agents 'borrowed' from other indications (such as hyperlipidaemia, inflammatory bowel disease or somatic pain) deserve further study.
conclusionsThere is reason for optimism in medical treatment of IBS with a spectrum of agents to treat bowel dysfunction. However, visceral analgesic treatments are still suboptimal.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.